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Stress echocardiography is the combination of 2D echocardiography with a physical, pharmacological or
electrical stress. The diagnostic end point for the detection of myocardial ischemia is the induction of a
transient worsening in regional function during stress. Stress echocardiography provides similar
diagnostic and prognostic accuracy as radionuclide stress perfusion imaging, but at a substantially
lower cost, without environmental impact, and with no biohazards for the patient and the physician.
Among different stresses of comparable diagnostic and prognostic accuracy, semisupine exercise is
the most used, dobutamine the best test for viability, and dipyridamole the safest and simplest pharma-
cological stress and the most suitable for combined wall motion coronary ﬂow reserve assessment. The
additional clinical beneﬁt of myocardial perfusion contrast echocardiography and myocardial velocity
imaging has been inconsistent to date, whereas the potential of adding – coronary ﬂow reserve evalu-
ation of left anterior descending coronary artery by transthoracic Doppler echocardiography adds
another potentially important dimension to stress echocardiography. New emerging ﬁelds of application
taking advantage from the versatility of the technique are Doppler stress echo in valvular heart
disease and in dilated cardiomyopathy. In spite of its dependence upon operator’s training, stress echo-
cardiography is today the best (most cost-effective and risk-effective) possible imaging choice to




Stress echo: a historical and socio-economic
perspective
In 1935, Tennant and Wiggers1 demonstrated that coronary
occlusion immediately resulted in instantaneous abnormal-
ity of wall motion. Experimental studies conducted some
40 years later on the canine model with ultrasonic crystals
and two-dimensional (2D) echocardiography proved that
during acute ischaemia2 and infarction,3 reductions in
regional ﬂow are closely mirrored by reductions in
contractile functions, and set the stage for the clinical use
of ultrasonic methods in ischaemic heart disease.
Initial reports describing echocardiographic changes during
ischaemia dealt with the use of M-mode techniques in
exercise-induced4 and vasospastic, variant angina.5 These
studies recognized for the ﬁrst time that transient dyssynergy
was an early, sensitive, speciﬁc marker of transient ischae-
mia, clearly more accurate than ECG changes and pain. The
clinical impact of the technique became more obvious in
the mid-80s with the combination of 2D echocardiography
with pharmacological stress, represented by dipyridamole6
or dobutamine7—both much less technically demanding
than treadmill exercise commonly used in the USA.8
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Stress echocardiography has evolved in Europe in a signiﬁ-
cantly different fashion from the USA. Pharmacological
stress echo has been widely accepted in clinical practice,
which has enabled us to collect a tremendous amount of
data from large scale, multicentre, effectiveness studies,
allowing to establish the safety and prognostic value of
stress echo in thousands of patients studied under ‘real
world conditions’.9,10 In European clinical practice, stress
echo has been embedded in the legal and cultural frame-
work of the existing European laws and medical imaging
referral guidelines. The use of radiation for medical examin-
ations and tests is the greatest man-made source of radi-
ation exposure.11 Small individual risks of each test
performed with ionizing radiation multiplied by a billion
examinations become signiﬁcant population risks. For this
reason, in Europe, both the law11 and the referral guidelines
for medical imaging12 recommend a justiﬁed, optimized,
and responsible use of testing with ionizing radiation. The
Euratom Directive 97/43 establishes that the indication
and execution of diagnostic procedures with ionizing radi-
ation should follow three basic principles: the justiﬁcation
principle (article 3: ‘if an exposure cannot be justiﬁed, it
should be prohibited’); the optimization principle (article
4: according to the ALARA principle, ‘all doses due to
medical exposures must be kept As Low As Reasonably
Achievable’), and the responsibility principle (article 5:
‘both the prescriber and the practitioner are responsible
for the justiﬁcation of the test exposing the patient to ionis-
ing radiation’). European Commission referral guidelines
were released in 2001 in application of the Euratom Direc-
tive and explicitly state that a non-ionizing technique
must be used whenever it will give grossly comparable infor-
mation with an ionizing investigation. For instance,
‘because MRI does not use ionizing radiation, MRI should
be preferred when both CT and MRI would provide similar
information and when both are available’.12
In this perspective of the medical, as well as socio-
economic and biological impact of medical imaging, it is
imperative to increase all efforts to improve appropriate-
ness13 and minimize the radiation burden of stress imaging
for the population and the individual patient.14 The impera-
tive of sustainability of medical imaging is likely to become
increasingly important in the near future, from a US per-
spective also.15,16 In the quest for sustainability, stress echo-
cardiography has unsurpassed assets of low cost, absence of
environmental impact, lack of biological effects for both the
patient17 and the operator compared with equally accurate,
but less sustainable, competing techniques.18
Pathophysiological mechanisms
Stress echocardiography is the combination of 2D echocar-
diography with a physical, pharmacological, or electrical
stress.19 The diagnostic endpoint for the detection of myo-
cardial ischaemia is the induction of a transient change in
regional function during stress. The stress echo sign of
ischaemia is a stress-induced worsening of function in a
region contracting normally at baseline. The stress echo
sign of myocardial viability is a stress-induced improvement
of function during low levels of stress in a region that is
abnormal at rest. A transient regional imbalance between
oxygen demand and supply usually results in myocardial
ischaemia, the signs and symptoms of which can be used
as a diagnostic tool. Myocardial ischaemia results in a
typical ‘cascade’ of events in which the various markers
are hierarchically ranked in a well-deﬁned time sequence.20
Flow heterogeneity, especially between the subendocardial
and subepicardial perfusion, is the forerunner of ischaemia,
followed by metabolic changes, alteration in regional mech-
anical function, and only at a later stage by electrocardio-
graphic changes, global left ventricular (LV) dysfunction,
and pain. The pathophysiological concept of the ischaemic
cascade is translated clinically into a gradient of sensitivity
of different available clinical markers of ischaemia, with
chest pain being the least and regional malperfusion the
most sensitive. This is the conceptual basis of the undis-
puted advantages of imaging techniques, such as perfusion
imaging or stress echocardiography over electrocardiogram
(ECG) for the noninvasive detection of coronary artery
disease.21 The reduction of coronary reserve is the
common pathophysiological mechanism. Regardless of the
stress used and the morphological substrate, ischaemia
tends to propagate centrifugally with respect to the ventri-
cular cavity:21,22 it involves primarily the subendocardial
layer, whereas the subepicardial layer is affected only at a
later stage if the ischaemia persists. In fact, extravascular
pressure is higher in the subendocardial than in the subepi-
cardial layer; this provokes a higher metabolic demand (wall
tension being among the main determinants of myocardial
oxygen consumption) and an increased resistance to ﬂow.
In the absence of coronary artery disease, coronary ﬂow
reserve (CFR) can be reduced in microvascular disease
(e.g. in syndrome X) or LV hypertrophy (e.g. arterial hyper-
tension). In this condition, angina with ST segment
depression can occur with regional perfusion changes, typi-
cally in the absence of any regional wall motion abnormal-
ities during stress. Wall motion abnormalities are more
speciﬁc than CFR and/or perfusion changes for the diagnosis
of coronary artery disease.23–28
Key point: Wall motion and perfusion (or CFR) changes
are highly accurate, and more accurate than ECG changes,
for detection and location of underlying coronary artery
disease. However, wall motion is more speciﬁc and
requires ischaemia; perfusion changes are more sensitive
and may occur in the absence of true ischaemia.
Ischaemic stressors
The three most common stressors are exercise, dobutamine,
and dipyridamole. Exercise is the prototype of demand-
driven ischaemic stress and the most widely used.
However, out of ﬁve patients, one cannot exercise, one
exercises submaximally and one has an uninterpretable
ECG. Thus, the use of an exercise-independent approach
allows diagnostic domain of a stress test laboratory to be
expanded.29,30 Pharmacological stressors minimize factors
such as hyperventilation, tachycardia, hypercontraction of
normal walls, and excessive chest wall movement which
render the ultrasonic examination difﬁcult during exercise.
All these factors degrade image quality and—in stress
echo—worse image quality dramatically leads to higher
interobserver variability and lower diagnostic accuracy.
Dipyridamole (or adenosine) and dobutamine act on
different receptor populations: dobutamine stimulates adre-
noreceptors whereas dipyridamole (which accumulates
endogenous adenosine) stimulates adenosine receptors.31
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They induce ischaemia through different haemodynamic
mechanisms: dobutamine primarily increases myocardial
oxygen demand32 and dipyridamole (or adenosine) mainly
decreases subendocardial ﬂow supply33 (Table 1). In the pre-
sence of coronary atherosclerosis, appropriate arteriolar
dilation can paradoxically exert detrimental effects on
regional myocardial layers or regions already well perfused
in resting conditions at the expense of regions or layers
with a precarious ﬂow balance in resting conditions.
In ‘vertical steal’, the anatomical requisite is the presence
of an epicardial coronary artery stenosis and the subepicar-
dium ‘steals’ blood from the subendocardial layers. The
mechanisms underlying vertical steal is a fall in perfusion
pressure across the stenosis. In the presence of a coronary
stenosis, the administration of a coronary vasodilator causes
a drop in post-stenotic pressure and, therefore, a critical
drop in subendocardial perfusion pressure, which in turn pro-
vokes a decrease in absolute subendocardial ﬂow, even with
subepicardial overperfusion. Regional thickening is closely
related to subendocardial rather than transmural ﬂow and
this explains the regional asynergy with ischaemia, despite
regionally increased transmural ﬂow. Since endocardial
oxygen demands are greater than epicardial, the resistance
vessels of the endocardium are more dilated than those of
the subepicardium, ultimately resulting in selective subendo-
cardial hypoperfusion. ‘Horizontal steal’ requires the pre-
sence of collateral circulation between two vascular beds
with the victim of the steal being the myocardium fed by
the more stenotic vessel. The arteriolar vasodilatory
reserve must be preserved, at least partially, in the donor
vessel and abolished in the vessel receiving collateral ﬂow.
After vasodilation, the ﬂow in the collateral circulation is
reduced in comparison with resting conditions. Despite the
different pathophysiological mechanism, ischaemia induction
when appropriately high doses with state-of-the-art protocols
are used, dipyridamole and dobutamine tests show a similar
diagnostic accuracy.34–37
Key point: Exercise, dobutamine, and vasodilators (at
appropriately high doses) are equally potent ischaemic
stressors for inducing wall abnormalities in the presence
of a critical epicardial coronary artery stenosis. Dobutamine
and exercise mainly act through increased myocardial
oxygen demand and dipyridamole and adenosine through
reduced subendocardial ﬂow supply subsequent to inap-
propriate arteriolar vasodilation and steal phenomena.
Diagnostic criteria
All stress echocardiographic diagnoses can be easily sum-
marized into equations centred on regional wall function
describing the fundamental response patterns as normal,
ischaemic, viable- and necrotic myocardium. In the normal
response, a segment is normokinetic at rest and normal or
hyperkinetic during stress. In the ischaemic response, a
segment worsens its function during stress from normokin-
esis to hypokinesis, akinesis, or dyskinesis (usually at least
two adjacent segments for test positivity are required)
(Table 2). In the necrotic response, a segment with resting
dysfunction remains ﬁxed during stress. In the viability
response, a segment with resting dysfunction may show
either a sustained improvement during stress indicating a
non-jeopardized myocardium (stunned) or improve during
early stress with subsequent deterioration at peak (biphasic
response). This response would indicate a jeopardized
region (hibernating myocardium) often improving after
revascularization.19,38 A resting akinesis which becomes dys-
kinesis during stress usually reﬂects a purely passive, mech-
anical consequence of increased intraventricular pressure
developed by normally contracting walls and should not be
considered a true active ischaemia.39
As with most imaging techniques, patient-dependent
factors can limit image quality in stress echocardiography,
which can adversely affect accuracy. Obesity and lung
disease, for example, may lead to poor acoustic windows
in 10% of patients. Harmonic imaging and ultrasound con-
trast agents for LV opaciﬁcation are now recommended to
enhance endocardial border detection. Given that the
interpretation of contractile function is subjective,
improved image quality can reduce interreader variability.
Key point: All stress echo responses follow four
basic patterns: normal (rest5stress5normal function);
ischaemia (rest5normal; stress5abnormal); necrotic
(rest5stress5abnormal); and viability (rest5abnormal;
stress5normal or biphasic).
Clear endocardial deﬁnition is crucial for optimal
interpretation and it is recommended that harmonic
imaging, when available, be routinely used for optimal
endocardial border detection. Contrast-enhanced endo-




During stress echo, electrocardiographic leads are placed at
standard limb and precordial sites, slightly displacing
(upward and downward) any leads that may interfere with
the chosen acoustic windows. A 12-lead ECG is recorded in
Table 1 Pharmacological stresses
Vasodilator Dobutamine

















Table 2 Stress echocardiography in four equations
Rest þ Stress ¼ Diagnosis
Normokinesis þ Normo-Hyperkinesis ¼ Normal
Normokinesis þ Hypo, A, Dyskinesis ¼ Ischaemia
Akinesis þ Hypo, Normokinesis ¼ Viable
A-, Dyskinesis þ A-, Dyskinesis ¼ Necrosis
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resting condition and each minute throughout the examin-
ation. An ECG lead is also continuously displayed on the
echo monitor to provide the operator with a reference for
ST segment changes and arrhythmias. Cuff blood pressure is
measured in resting condition and each stage thereafter.
Echocardiographic imaging is typically performed from the
parasternal long- and short-axis, apical long-axis, and apical
four- and two-chamber views. In some cases, the subxyphoi-
dal and apical long-axis views are used. Images are recorded
in resting condition from all views and captured digitally. A
quad-screen format is used for comparative analysis. Record-
ing on video tape alone is not sufﬁcient and may be used as a
back-up medium only in cases of technical failure.40
Echocardiography is then continuously monitored and
intermittently stored. In the presence of obvious or sus-
pected dyssynergy, a complete echo examination is per-
formed and recorded from all employed approaches to
allow optimal documentation of the presence and extent
of myocardial ischaemia. These same projections are
obtained and recorded during the recovery phase, after ces-
sation of stress (exercise or pacing) or administration of the
antidote (aminophylline for dipyridamole, b-blocker for
dobutamine, nitroglycerine for ergometrine),40,41 an ischae-
mic response may occasionally occur late, after cessation of
drug infusion.41 In this way, the transiently dyssynergic area
during stress can be evaluated by a triple comparison: stress
vs. resting state; stress vs. recovery phase; and at peak
stress. It is critical to obtain the same views at each stage
of the test. Analysis and scoring of the study are usually per-
formed using a 16- or 17-segment model of the left ventri-
cle42 and a four-grade scale of regional wall motion analysis.
Diagnostic endpoints of stress echocardiographic testing
are: maximum dose (for pharmacological) or maximum
workload (for exercise testing): achievement of target
heart rate; obvious echocardiographic positivity (with akin-
esis of 2 LV segments); severe chest pain; or obvious elec-
trocardiographic positivity (with .2 mV ST segment shift).
Submaximal non-diagnostic endpoints of stress echo
testing are non-tolerable symptoms or limiting asympto-
matic side effects such as hypertension, with systolic
blood pressure .220 mmHg or diastolic blood pressure.120
mmHg, symptomatic hypotension, with .40 mmHg drop in
blood pressure; supraventricular arrhythmias, such as supra-
ventricular tachycardia or atrial ﬁbrillations; and complex
ventricular arrhythmias, such as ventricular tachycardia or
frequent, polymorphic premature ventricular beats.
Key point: Standardized protocols for stress echocar-
diography are required to conduct a safe study with
optimal diagnostic accuracy. Careful monitoring of vital
signs (clinical status, heart rate, blood pressure, and
ECG beyond echo) is required during stress echocardio-
graphy, which should be done by cardiologists with Basic
Life Support and Advanced Cardiac Life Support training.
Speciﬁc test protocols
The most frequently used stressors for echocardiographic
tests are exercise, dobutamine, and dipyridamole.
Exercise
Exercise echocardiography can be performed using either a
treadmill or a bicycle protocol. When a treadmill test is per-
formed, scanning during exercise is not feasible, so most
protocols rely on immediate post-exercise imaging. It is
imperative to accomplish post-exercise imaging as soon as
possible (1 min from cessation of exercise). To accomplish
this, the patient is moved immediately from the treadmill to
an imaging bed and placed in the left lateral decubitus pos-
ition so that imaging may be completed within 1–2 min. This
technique assumes that regional wall motion abnormalities
will persist long enough into recovery to be detected.
When abnormalities recover rapidly, false-negative results
occur. The advantages of treadmill exercise echocardiogra-
phy are the widespread availability of the treadmill system
and a greater feasibility due to the fact that a number of
patients are unable to cycle. Information on exercise
capacity, heart rate response, and rhythm and blood
pressure changes are analysed and, together with wall
motion analysis, become part of the ﬁnal interpretation.
Bicycle exercise echocardiography is performed during
either an upright or a recumbent posture. The patient
pedals against an increasing workload at a constant
cadence (usually 60 rpm). The workload is escalated in a
stepwise fashion while imaging is performed. Successful
bicycle stress testing requires co-operation of the patient
(to maintain the correct cadence) and co-ordination (to
perform pedalling action). The most important advantage
of bicycle exercise is the chance to obtain images during
the various levels of exercise (rather than relying on post-
exercise imaging). Although imaging can be done throughout
the exercise protocol, in most cases, interpretation is based
on a comparison of resting and peak exercise images. In the
supine posture, it is relatively easy to record images from
multiple views during graded exercise. With the develop-
ment of ergometers that permit leftward tilting of the
patients, the ease of image acquisition has been further
improved. In the upright posture, imaging is generally
limited to either apical or subcostal views. By leaning the
patient forward over the handlebars and extending the
arms, apical images can be obtained in the majority of
patients. To record subcostal views, a more lordotic position
is necessary and care must be taken to avoid foreshortening
of the apex.
Dobutamine
The standard dobutamine stress protocol usually adopted
consists of continuous intravenous infusion of dobutamine
in 3 min increments, starting with 5 mg/kg/min and increas-
ing to 10, 20, 30, and 40 mg /kg/min (Figure 1). If no end-
point is reached, atropine (in doses 0.25 mg up to a
Figure 1 State-of-the art protocol of dobutamine stress
echocardiography.
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maximum of 1 mg) is added to the 40 mg/kg/min dobuta-
mine infusion. Other more conservative protocols—with
longer duration of steps and peak dobutamine dosage of
20–30 mg/kg/min—have been proposed but are limited by
unsatisfactory sensitivity. More aggressive protocols—with
higher peak dosage of dobutamine up to 50–60 mg /kg/min
and atropine sulphate up to 2 mg—have also been proposed,
but safety concern remains and to date no advantages have
been shown in larger studies.
Dipyridamole
The standard dipyridamole protocol consists of an intrave-
nous infusion of 0.84 mg/kg over 10 min, in two separate
infusions: 0.56 mg/kg over 4 min (‘standard dose’), followed
by 4 min of no dose and, if still negative, and additional
0.28 mg/kg over 2 min. If no endpoint is reached, atropine
(doses of 0.25 mg up to a maximum of 1 mg) is added. The
same overall dose of 0.84 mg/kg can be given over 6 min—
the shorter the infusion time, the higher the sensitivity43
(Figure 2). Aminophylline (240 mg iv) should be available
for immediate use in case an adverse dipyridamole-related
event occurs and routinely infused at the end of the test
independent of the result.
Adenosine
Adenosine can be used in a similar manner and is typically
infused at a maximum dose of 140 mg/kg/min over 6 min.
Imaging is performed prior to and after starting adenosine
infusion.
Pacing
The presence of a permanent pacemaker can be exploited to
conduct a pacing stress test in a totally non-invasive manner
by externally programming the pacemaker to increasing fre-
quencies.44 Pacing is started at 100 bpm and increased every
2 min by 10 bpm until the target heart rate (85% of age-
predicted maximal heart rate) is achieved or until other
standard endpoints are reached. The same protocol can
also be followed in an accelerated fashion, with faster
steps (20–30 s each), up to the target heart rate. A limiting
factor is, however, that several pacemakers cannot be pro-
grammed to the target heart rate. This should be checked
before the patient is scheduled for such a test. Two-
dimensional echocardiographic images are obtained before
pacing and throughout the stress test with the ﬁnal record-
ing being obtained after 3 min of pacing at the highest rate
reached (usually 150 bpm) or the target heart rate.
Test for vasospasm: ergometrine
A bolus injection of ergometrine (50 mg) is administered
intravenously at 5 min intervals until a positive response is
obtained or a total dose of 0.35 mg is reached. The
12-lead ECG is recorded after each ergonovine injection
and LV wall motion is monitored continuously. Positive cri-
teria for the test include the appearance of transient
ST-segment elevation or depression .0.1 mV at 0.08 s
after the J point (ECG criteria) or reversible wall motion
abnormality by 2D echocardiography (echocardiographic cri-
teria). The criteria for terminating the test are as follows:
positive response deﬁned as ECG or echocardiographic cri-
teria, total cumulative dose of 0.35 mg ergonovine, or
development of signiﬁcant arrhythmia or changes in vital
signs (systolic blood pressure .200 mmHg or ,90 mmHg).
An intravenous bolus injection of nitroglycerin is adminis-
tered as soon as an abnormal response is detected; sublin-
gual nifedipine (10 mg) is also recommended to counter
the possible delayed effects of ergometrine.45,46 These
drugs can be administered as required.
Key points: Maximal, symptom-limited tests are
required to optimize accuracy of stress echo. Semi-supine
exercise is the preferred option for physical exercise.
Both dobutamine and dipyridamole should be performed
with high-dose protocols to obtain high sensitivities, com-
parable with maximal exercise.
Diagnostic accuracy
Exercise,47–66 high-dose dobutamine,30,34,58,63–110 and high-
dose (accelerated or with atropine) dipyrida-
mole6,29,34,50,64,70,74,92–120 have not only similar accuracies,
but also similar sensitivities36,120 (Tables 3 and 4). Familiarity
with all forms of stress is an index of the quality of the
echo lab. In this way, indications in the individual
patient can be optimized, thereby avoiding the relative
and absolute contraindications of each test. For instance,
a patient with severe hypertension and/or a history of
Figure 2 State-of-the art protocol of dipyridamole stress echocardiography.
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Table 3 Dipyridamole-stress vs dobutamine-stress echocardiography for detection of coronary artery disease
Sn (%), n Sn 1 v (%), n Sn multiv (%), n Sp (%), n Acc (%), n
Dip Dop Dip Dop Dip Dop Dip Dop Dip Dop
Salustri et al.70 82, 23/28 79, 22/28 50, 5/10 40, 4/10 72, 13/18 67, 12/18 89, 16/18 78, 14/18 85, 39/46 72, 36/46
Pingitore et al.34 82, 75/92 84, 77/92 71, 29/41 78, 32/41 91, 46/51 87, 44/51 94, 17/18 89, 15/18 84, 92/110 84, 92/110
San Roman et al.115 81, 54/66 78, 52/66 68, 22/32 75, 24/32 94, 32/34 82, 28/34 94, 34/36 88, 32/36 86, 88/102 82, 82/102
Loimaala et al.118 93, 41/44 95, 42/44 92, 24/26 92, 24/26 94, 17/18 100, 18/18 75, 12/16 63, 10/16 87, 53/60 88, 52/60
Nedeljcovic et al.119 96, 66/69 93, 64/69 95, 54/57 95, 54/57 100, 12/12 100, 12/12 92, 44/48 92, 44/48 91, 107/117 94, 110/117
Total 87, 259/299 86, 257/299 81, 134/166 83, 138/166 90, 120/133 86, 114/133 90, 123/136 84, 115/136 87, 379/435 85, 372/435
Table 4 Dipyridamole (DIP) stress vs exercise (EXE) stress echocardiography for detection of coronary artery disease
Study Sensitivity Speciﬁcity Accuracy Feasibility
Single vessel Multivessel Global
DIP EXE DIP EXE DIP EXE DIP EXE DIP EXE DIP EXE
Picano et al.23 6/13 (46%) 8/13 (62%) 12/12 (100%) 11/12 (92%) 18/25 (72%) 19/25 (76%) 15/15 (100%) 13/15 (87%) 33/40 (83%) 32/40 (80%) 55/55 (100%) 40/55 (73%)
Deutsch et al.117 19/30 (63%) 20/30 (67%) 18/21 (86%) 18/21 (86%) 37/51 (73%) 38/51 (75%) 13/15 (87%) 12/15 (80%) 50/66 (76%) 50/66 (76%) 74/80 (95%) 66/80 (84%)
Marangelli et al.52 4/16 (25%) 13/16 (81%) 11/19 (58%) 18/19 (95%) 15/35 (43%) 31/35 (89%) 23/25 (92%) 22/25 (88%) 38/60 (63%) 53/60 (88%) 80/82 (92%) 84/100 (84%)
Beleslin et al.51 78/108 (72%) 95/108 (88%) 10/11 (91%) 10/11 (91%) 88/119 (74%) 105/119 (88%) 16/17 (94%) 14/17 (82%) 105/136 (77%) 118/136 (87%)
Dagianti et al.64 3/10 (30%) 7/10 (70%) 10/15 (70%) 12/15 (80%) 13/25 (52%) 19/25 (76%) 34/35 (97%) 33/35 (94%) 47/60 (78%) 52/60 (87%) 60/60 (100%) 57/60 (95%)
Bjornstad et al.59 21/31 (68%) 26/31 (84%) 6/6 (100%) 4/6 (67%) 27/37 (73%) 30/37 (81%)
Schroder et al.95 50/65 (77%) 35/65 (53%) 8/9 (89%) 8/9 (89%) 58/74 (78%) 43/74 (58%) 119/121 (98%) 74/83 (89%)
Loimaala et al.118 24/26 (92%) 23/26 (88%) 17/18 (94%) 17/18 (94%) 41/44 (93%) 40/44 (91%) 12/16 (75%) 7/16 (44%) 53/60 (88%) 47/60 (78%)
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signiﬁcant atrial or ventricular arrhythmias can more
reasonably undergo to the dipyridamole stress test which,
unlike dobutamine, has no arrhythmogenic or hypertensive
effect. In contrast, a patient with severe conduction dis-
turbances or advanced asthmatic disease should undergo
the dobutamine stress test, since adenosine has a negative
chronotropic and dromotropic effect, as well as a documen-
ted bronchoconstrictor activity. Patients either taking
xanthine medication or under the effect of caffeine con-
tained in drinks (tea, coffee, and cola) should undergo the
dobutamine test. Both dipyridamole and dobutamine have
overall tolerance and feasibility. The choice of one test
over the other depends on patient characteristics, local
drug cost, and the physician’s preference. It is important
for all stress echocardiography laboratories to become fam-
iliar with all stresses to achieve a ﬂexible and versatile diag-
nostic approach that enables the best stress to be tailored to
individual patient needs. Antianginal medical therapy (in
particular, beta-blocking agents) signiﬁcantly affects the
diagnostic accuracy of all forms of stress; therefore, it is
recommended, whenever possible, to withhold medical
therapy at the time of testing to avoid a false-negative result.
Key point: Physical or pharmacological (inotropic or
vasodilator) stress echocardiography have comparable
diagnostic accuracies. The choice of one test over the
other will depend on relative contraindications. Large-
volume laboratories should be fully acquainted with all
the three main forms of stress in order to apply the test
in all patients. In the presence of a submaximal ﬁrst-line
stress for limiting side effects, the second choice should
be applied, since submaximal (physical or pharmacologi-
cal) stresses have suboptimal diagnostic value.
Prognostic value of inducible myocardial
ischaemia
The presence (or absence) of inducible wall motion
abnormalities separates patients with different prognoses.
Information has been obtained from data banks of thousands
of patients—also with multicentre design—for exercise,121–
137 dobutamine,83,138–191 and dipyridamole.34,158,159,164,167–
169,188,192–222 A normal stress echocardiogram yields an
annual risk of 0.4–0.9% based on a total of 9000 patients,137
the same as for a normal stress myocardial perfusion scan.
Thus in patients with suspected coronary artery disease, a
normal stress echocardiogram implies excellent prognosis
and coronary angiography can safely be avoided. The positive
and the negative response can be further stratiﬁed with inter-
actions with clinical parameters (diabetes, renal dysfunction,
and therapy at the time of test), resting echo (global LV
function), and additive stress echo parameters (LV cavity
dilatation, CFR, and previous revascularization).223–229
The established prognostic stress echo parameters with
their relative event rate are shown in Tables 5 and 6.
Key point: Physical or pharmacological (inotropic or
vasodilator) stress echocardiography have a comparable
prognostic power of stratiﬁcation. The most extensive
evidence is available with dipyridamole, dobutamine,
and exercise tests. A normal baseline and stress echocar-
diogram gives an annual risk for death of 0.4–0.9%, the
same as for a normal stress myocardial perfusion scan.
Thus, in patients with suspected coronary artery
disease, a normal stress echocardiogram implies an excel-
lent prognosis and coronary angiography can safely be
avoided.
Indications and prognostic value of myocardial
viability assessment
By far, the widest experience is available with low-dose
dobutamine stress echocardiography,7,230–266 the preferred
stressor for assessing myocardial viability. However, it is
also possible to assess the presence of myocardial viability
using low-dose dipyridamole or low-level exercise or
enoximone.267–272
In the setting of ischaemia, loss of myocardial contractile
function may be due to myocardial necrosis, stunning, or
hibernation. Whereas myocardial necrosis usually alludes
to irreversible myocardial dysfunction, stunning and
hibernation reﬂect reversibility of myocardial function.
Revascularization of chronically, but reversibly, dysfunc-
tional myocardium, often referred to as hibernating or
viable, has emerged as an important alternative in the
treatment of heart failure secondary to coronary artery
disease. Observational studies have indeed suggested that
patients with ischaemic LV dysfunction and a signiﬁcant
amount of viable myocardium (at least ﬁve segments or a
WMSI .0.25)250–266 have lower perioperative mortality,
greater improvements in regional and global LV function,
fewer heart failure symptoms, and improved long-term sur-
vival after revascularization than patients with large areas
of non-viable myocardium.








Resting EF .50% ,40%
Anti-ischaemic therapy Off On
CFR .2.0 ,2.0
CFR, coronary ﬂow reserve.
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LAD, left anterior descending artery; LCx, left circumﬂex; RCA, right
coronary artery.
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The protocol in most stress echocardiography laboratories
uses dobutamine infusion at two low-dose stages (5 and
10 mg/kg/min), with each stage lasting 3 min. Some advo-
cate using an even lower starting dose of 2.5 mg/kg/min
since in patients with critical coronary stenosis, myocardial
ischaemia may be precipitated even with doses as low as
5 mg/kg/min. The beneﬁt of proceeding to higher doses of
dobutamine, even if contractile reserve is demonstrated at
lower doses, is to observe a ‘biphasic response’. It is not sur-
prising that the biphasic response has the best predictive
value of all the possible responses to dobutamine in deter-
mining improvement in LV function following revasculariza-
tion. In a recent study, ,15% of myocardial segments
demonstrating either no change or sustained improvement
with low- and high-dose dobutamine had functional recovery
with revascularization, whereas 72% of segments with a
biphasic response recovered function.266 Thus, the com-
bined low- and high-dose approach in all patients who do
not have contraindications should be recommended.
Key point: Dobutamine stress echocardiography is by
far the most widely used method for assessing viable
myocardium. This is mandatory in patients with LV dys-
function who may beneﬁt from coronary revasculariza-
tion. When dobutamine is contraindicated or not well
tolerated, several other stresses (low-level exercise, ade-
nosine, dipyridamole, and enoximone) can be used to
elicit a regional inotropic reserve in viable myocardium.
The diagnostic and prognostic value of CFR
during vasodilator stress testing
Stress testing of CFR introduces a change in the choice of
stress, the use of transducers, and the methodology of
testing.273–275 Besides the classic projections for stress
echocardiography testing, speciﬁc projection for left
anterior descending (LAD) coronary artery imaging should
be integrated into the cardiac imaging sequence. The pos-
terior descending artery and the left circumﬂex artery can
be imaged with dedicated imaging projections, but with
greater difﬁculty and a lower success rate. The use of CFR
as a ‘stand-alone’ diagnostic criterion suffers from so
many structural limitations that render it little more than
an academic assumption: ﬁrst, only the LAD is sampled;
and secondly, the CFR cannot distinguish between microvas-
cular and macrovascular coronary disease.276 Therefore, it is
much more interesting (and clinically realistic) to evaluate
the additive value over conventional wall motion for LAD
detection. The assessment of CFR adds sensitivity for LAD
disease—with a modest loss in speciﬁcity. Coronary ﬂow
reserve and wall motion analysis offer, under many
aspects, complementary information during stress echo.
From the pathophysiological viewpoint, wall motion positiv-
ity requires ischaemia as a necessary pre-requisite, whereas
CFR can be impaired in the absence of induced ischaemia. A
normal CFR has a higher negative predictive value. There-
fore, the two pieces of information on ﬂow and function
can complement each other, since a wall motion abnormal-
ity is more efﬁcient to include coronary artery disease and a
normal CFR is more efﬁcient to exclude it.273–275 In patients
with idiopathic dilated cardiomyopathy,277,278 an abnormal
CFR during dipyridamole infusion identiﬁes a subgroup at
high risk of developing progressive ventricular deterioration
and heart failure. In the same subset of patients, the combi-
nation of the two parameters has an added value and is
complementary in its power of prognostication.278 The com-
bination of conventional wall motion analysis with 2D-echo
and CFR with pulsed Doppler ﬂowmetry of mid-distal LAD
artery has been shown to provide an added and complemen-
tary power of prognostication in patients with known or sus-
pected coronary artery disease.279,280 A reduced CFR is an
additional parameter of ischaemia severity in the risk strati-
ﬁcation of the stress echocardiographic response whereas
patients with a negative test for wall motion criteria and
normal CFR have a favourable outcome during dipyridamole
stress echocardiography.
Key point: Whenever suitable technology and dedicated
expertise are available, it is recommended to perform
dual imaging vasodilator stress echocardiography for diag-
nostic and prognostic purposes. Coronary ﬂow reserve on
LAD territory is highly feasible in expert hands, and is not
useful as a stand-alone diagnostic criterion due to low
speciﬁcity and LAD-limited information; however, it
does add critical prognostic value when added to conven-
tional wall motion analysis exploring all LV territories.
Safety of pharmacological stress
echocardiography
Minor, but limiting, side effects preclude the achievement of
maximal pharmacological stress in ,10% of patients with
dobutamine9 and ,5% in patients with dipyridamole
stress.281–295 The most frequent minor and major compli-
cations during stress echo and their frequencies are shown
in Tables 7–9. The data emphasize some obvious, albeit
sometimes neglected, points. First, pharmacological stress
tests should always be performed with an attending
Table 7 Life-threatening complications in single-center
experience (.1000 patients), multicenter studies (EDIC), and
multicenter registries for dobutamine stress echocardiography
Study Patients Complication(s)
Single institution experience
Mertes et al.283 1118 Nonea
Pellikka et al.284 1000 1 AMI, 4 VT, 1 prol
ischaemia
Zahn et al.285 1000 1 VF, 1LVF, 1 seizure
Seknus and Marwick286 3011 5 VT, 1 AMI, 1 prol
ischaemia, 1 hypo
Elhendy et al.287 1164 7 VT
Bremer et al.288 1035 1 VF, 1 VT
Poldermans et al.289 1734 3 VF, 13 VT, 6 hypo
Mathias et al.290 4033 1 VFm 8 VT, 1 MI; 5 atropine
intoxications
Multicenter registry
Picano et al.9 2949 2 VF, 2 VT, 2 AMI, 1 prol
ischaemia, 1 hypo
Pezzano et al. (RITED)
1994
3041 2 VF, 1 asystole
Beckmann et al.292 9354 324 (2 VF)
Varga et al.295 35 103 63 (5 deaths)
Total 64 542 461
aNo life-threatening complications reported; however, minor and self-
limiting adverse effects were documented.
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physician present. Secondly, every test carries a deﬁnite,
albeit minor risk. Thirdly, not all stress tests carry the
same risk of major adverse reactions and dobutamine
stress testing may be more dangerous than other forms of
pharmacological stress, such as those produced by dipyrida-
mole or adenosine. These conclusions come convergently
from multicenter trials, meta-analyses of published litera-
ture and the Registry of Complications based on prospective
data acquisition (German Registry) and retrospective data
retrieval. Physical stress with exercise is probably safer
than pharmacological testing.294,295
Key point: Exercise is safer than pharmacological
stress. Among pharmacological stresses, dipyridamole is
safer than dobutamine. Both the doctor and the patient
should be aware of the rate of complications—and the
rate of complications (derived from literature and from
the lab experience) should be spelled out in the informed
consent.
Indication to stress echo
Indications for stress echocardiography can also be grouped
in very broad categories, which could eventually encompass
the overwhelming majority of patients:
(i) coronary artery disease diagnosis;
(ii) prognosis and risk stratiﬁcation in patients with estab-
lished diagnosis (e.g. after myocardial infarction);
(iii) preoperative risk assessment;
(iv) evaluation for cardiac aetiology of exertional
dyspnoea;
(v) evaluation after revascularization;
(vi) ischaemia location;296
(vii) evaluation of heart valve stenosis severity.
As a rule, the less informative the exercise ECG test is, the
stricter the indication for stress echocardiography will be.
The three main speciﬁc indications for stress echocardiogra-
phy can be summarized as follows:
(i) patients in whom the exercise stress test is contraindi-
cated (e.g. patients with severe arterial hypertension);
(ii) patients in whom the exercise stress test is not feasible
(e.g. those with intermittent claudication);
(iii) patients in whom the exercise stress test was non-
diagnostic or yielded ambiguous results:
(iv) left bundle branch block or signiﬁcant resting ECG
changes that makes any ECG interpretation during
stress difﬁcult;
(v) submaximal stress ECG.
Stress echocardiography yields the greatest incremental
diagnostic and prognostic value in patients in whom exercise
electrocardiography is a non-diagnostic, ambiguous, or
inconclusive. Pharmacological stress echocardiography is
the choice for patients in whom exercise is unfeasible or
contraindicated. The results of physical and pharmacologi-
cal stress echo should be used in both in- and out-patients
as ‘a gatekeeper’ to coronary angiography. In fact, for any
given coronary anatomy, the prognostic beneﬁt of recanali-
zation is much higher with documented ischaemia on stress
testing. Patients with stress echo positivity, especially those
with a ‘high-risk’ positivity pattern (occurring at low dose or
workload, with slow recovery and/or antidote resistance,
with akinesis or dyskinesis of more than ﬁve segments of
the left ventricle), should be referred to coronary angiogra-
phy. In Table 10, several clinical targets of stress echocar-
diography are reported.
Keypoint: Stress echocardiography should not be used as
a ﬁrst-line imaging technique for diagnostic and prognostic
purposes in patients with known or suspected coronary
artery disease but only when exercise ECG stress test is
either non-diagnostic or non-interpretable (e.g. for left
Table 9 Safety proﬁle of pharmacologic stress
echocardiography
Dobutamine Dipyridamole
% submaximal tests 10 5
Side effects 1/300 exams 1/1000
TV, FV þþ þ
High grade AV block þ þþ
Death 1/5000 1/10 000
Table 8 Life-threatening complications in multicenter studies




Picano et al.281 10 451 1 cardiac death, 1




Varga et al.295 24 599 19 (1 death)
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CW, continuous wave Doppler; DC, dilated cardiomyopathy; DOB, dobuta-
mine; DIP, dipyridamole; EX, exercise; HCM, hypertrophic cardiomyopathy;
Hyperv, hyperventilation; LAD, left anterior descending coronary artery;
PW, pulsed wave Doppler; TR, tricuspid regurgitation; WM, wall motion.
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bundle branch block or pacemaker). The less informative
and/or interpretable exercise electrocardiography is




The application of stress echocardiography to valvular heart
disease is still a moving target and not all guidelines297,298
recognize a speciﬁc role for this technique in the work-up
of patients. In fact, the ESC document does not recognize
any role for stress echocardiography in this set of patients,
whereas the AHA/ACC document deﬁnes particular subsets
in which stress echocardiographic parameters are used in
surgical decision-making.
Role of stress Doppler echocardiography in the evaluation
of aortic stenosis severity in patients with low-transvalvular
rates and gradients and left ventricular dysfunction and in
asymptomatic patients with severe aortic stenosis
In several speciﬁc cases, such as in patients with low-
gradient aortic stenosis, the use of stress echocardiography
in the decision-making process has signiﬁcantly modiﬁed the
outcome of patients. In selected patients with low-ﬂow/
low-gradient aortic stenosis and LV dysfunction, it may be
useful to determine the transvalvular pressure gradient
and to calculate valve area during a baseline state and
again during exercise or low-dose pharmacological (i.e.
dobutamine infusion) stress, with the goal of determining
whether stenosis is severe or only moderate in severity.299–310
This approach is based on the notion that patients who do
not have true anatomically severe stenosis will exhibit an
increase in the valve area and little change in gradient
during an increase in stroke volume.300–303 Thus, if a dobu-
tamine infusion produces an increase in stroke volume and
an increase in valve area .0.2 cm2 and little change in gra-
dient, it is likely that baseline evaluation overestimated the
severity of stenosis. In contrast, patients with severe aortic
stenosis will have a ﬁxed valve area with an increase in
stroke volume and an increase in gradient. These patients
are likely to respond favourably to surgery. Patients who
fail to show an increase in stroke volume with dobutamine
(,20%), referred to as ‘lack of contractile reserve’,
appear to have a very poor prognosis with either medical
or surgical therapy.305,309 Although patients with low-output
severe aortic stenosis have a poor prognosis, in those with
contractile reserve, outcome is still better with aortic
valve replacement than with medical therapy. The manage-
ment decisions in patients with low-gradient aortic stenosis
should therefore take into account the results of dobuta-
mine echocardiograms (Table 11). The management of
asymptomatic patients with aortic stenosis remains a source
of debate. The wide variation in their individual outcome
has recently raised the question of early elective surgery. In
this respect, exercise testing is an interesting tool, and
several studies have shown its prognostic value. When
combined with pre-exercise imaging, it seems to provide
incremental prognostic value when compared with either
resting echo data or exercise ECG results. A reduced exercise
tolerance, with development of dyspnoea or ST segment
depression, is associated with a worse outcome. On top of
this conventional, established information, a mean pressure
gradient rise .20 mmHg may contribute to a worse
prognostic outcome and possibly favour early replacement
in borderline cases.311 More conﬁrmatory, data are required
to incorporate this parameter into the daily work-up of the
asymptomatic aortic stenosis patients with high gradients.
Key point: In the presence of LV dysfunction and
low-gradient aortic stenosis, low-dose dobutamine stress
echocardiography is recommended to assess stenosis
severity. In asymptomatic patients with severe aortic ste-
nosis, exercise echo may play a role in decision-making.
Role of stress Doppler echocardiography in the evaluation
of patients with mitral stenosis and discordant symptoms
and stenosis severity.
A baseline resting transthoracic echocardiography exam-
ination usually sufﬁces for dictating management in asymp-
tomatic patients with mild stenosis (who are left on medical
therapy) and in symptomatic patients with moderate-to-
severe stenosis, who are candidates for either percutaneous
or surgical mitral valve repair. In a few patients, there may
nonetheless be a need for a more detailed evaluation of the
haemodynamic consequences of the stenosis, whenever the
symptomatic status does not ﬁt with stenosis severity. In
asymptomatic patients with severe stenosis (mean gradient
.10 mmHg and mitral valve area below 1.0 cm2), or sympto-
matic patients with moderate stenosis (with mean gradient
between 5 and 10 mmHg and mitral valve area between
1.0 and 1.5 cm2), the measurement of pulmonary pressures
during exercise (or dobutamine) may help distinguish those
who could beneﬁt from surgery from those who should
continue on medical treatment.312–314 In these patients,
measurement of systolic pulmonary pressure (from the tricus-
pid regurgitant ﬂow velocity) and transmitral pressure gradi-
ent during exercise may be used as surrogates to the invasive
measurements, thus avoiding cardiac catheterization.
Key point: Exercise (or dobutamine) echocardiography
with focus on transmitral pressure gradient and pulmon-
ary pressure is useful in assessing the nature of symptoms
in patients with mitral stenosis still in the grey zone
between valve repair and medical treatment after rest
evaluation.
Stress Doppler echocardiography for the evaluation of
patients with regurgitant lesions.
In very selected cases, when symptoms are discrepant
with the severity of the regurgitant lesion, stress echocar-
diography may prove to be a useful tool for identifying
patients with a worse prognosis. Indeed the lack of contrac-
tile reserve—failure to increase LV ejection fraction during
exercise—unmasks patients with latent LV dysfunction who
might be referred for surgery.315–320 The lack of contractile
Table 11 Dobutamine stress echo in low gradient, low ﬂow
aortic stenosis
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reserve and a rise in pulmonary artery systolic pressure
during exercise .60 mmHg unmasks patients with latent
LV dysfunction who might be referred for surgery.298 Exer-
cise echocardiography has been used to reveal the presence
of severe mitral regurgitation with exercise in patients with
rheumatic mitral valve disease and only mild mitral stenosis
and regurgitation at rest.315 Similarly, exercise echocardio-
graphy is of value in identifying haemodynamically signiﬁ-
cant dynamic mitral regurgitation in patients with LV
systolic dysfunction. In some patients, dynamic mitral regur-
gitation can account for acute pulmonary oedema and pre-
dicts poor outcome. Patients who presented an increase in
the effective regurgitant oriﬁce or systolic pulmonary
pressure at peak exercise had a higher incidence of morbid-
ity and mortality.317 As in patients with chronic mitral regur-
gitation, the development of irreversible LV dysfunction is a
major concern in the management of asymptomatic patients
with severe aortic regurgitation. In patients with normal
function at rest, a stress-induced increase in contractile
reserve, following exercise or dobutamine, before surgery
predicts improvement in LV function after valve replace-
ment surgery. The usefulness of contractile reserve can be
extended to the evaluation of aortic regurgitation patients
who have developed LV dysfunction. Any increase in ejection
fraction during dobutamine stress echocardiography pre-
dicted favourable outcome after surgery and a return to sys-
tolic function. Despite these data, the role of stress testing
is less well established in patients with aortic regurgitation
than in those with mitral regurgitation.
Key point: Stress echocardiography has been shown to
be useful for the assessment of regurgitant valve lesions
when symptoms do not ﬁt with severity at rest
echocardiography.
Non-cardiac surgery
Patients undergoing non-cardiac surgery are at signiﬁcant
risk of cardiovascular morbidity and mortality. Perioperative
myocardial infarction is the most frequent complication in
this respect. Evidence exists that coronary plaque rupture,
leading to thrombus formation and subsequent vessel occlu-
sion, is the dominant causative mechanism behind such an
event, similar to myocardial infarctions occurring in non-
surgical settings. The incidence of plaque rupture is trig-
gered by the perioperative stress response, which includes
a cytokine response, catecholamine surge with associated
haemodynamic stress, vasospasm, reduced ﬁbrinolytic
activity, platelet activation, and consequent hypercoagul-
ability. This mechanism is responsible for half of all
adverse perioperative cardiac events. In patients with
established coronary artery disease, perioperative infarc-
tion may also be caused by a sustained myocardial supply/
demand imbalance due to prolonged tachycardia and
increased myocardial contractility. From the epidemiologi-
cal viewpoint, coronary disease is known to be the leading
cause of perioperative mortality and morbidity following
vascular and general surgery.321 The diagnostic/therapeutic
corollary of these considerations is that coronary artery
disease—and therefore the perioperative risk—in these
patients has to be effectively identiﬁed preoperatively. In
low and intermediate risk patients, with an estimated peri-
operative cardiac risk of ,5%, this can be accurately done
with clinical scores (such as Detsky’s or Goldman’s score),
electrocardiography, and rest echocardiography. However,
in patients with an estimated cardiac risk of more than 5%
additional ischaemic-provocative tests are recommended.
Pharmacological stress echocardiography appears to be the
ﬁrst choice as it combines information on valve abnormal-
ities and myocardial ischaemia. Exercise stress has limit-
ations, due to the limited exercise capacity, mainly
related to the indication of surgery such as arthritis and vas-
cular disease. Nuclear scintigraphy has comparable prognos-
tic value with pharmacological stress echocardiography for
the identiﬁcation of stress-induced ischaemia.322 Experience
either with dipyridamole201–206 or dobutamine154,160,323–326
unequivocally indicates that these tests have a very high
negative predictive value (between 90 and 100%); a negative
test is associated with a very low incidence of cardiac events
and permits a safe surgical procedure. Usefulness in the risk
stratiﬁcation is high for perioperative events and remains
excellent also for long-term follow-up.156,327 To date, it
does not appear reasonable to perform coronary revascular-
ization prior to peripheral vascular surgery in patients with a
positive stress echocardiography result, with the exception
of those with test results suggestive of left main disease or
an equivalent such as two-vessel disease with proximal ste-
nosis in the LAD.328–330 A more conservative approach—with
watchful cardiological surveillance coupled with pharmaco-
logical cardioprotection with cardioselective b-blockers and
statins—can be adopted in patients with less severe ischae-
mic responses during stress.331,332 Risk stratiﬁcation with
pharmacological stress echocardiography should probably
be targeted at patients over 70 years of age, with current
or previous angina pectoris, and previous myocardial infarc-
tion and heart failure. In other patients, the event rate using
b-blocker therapy is so low that an indiscriminate risk stra-
tiﬁcation policy with stress echocardiography is probably
untenable.333
Key point: Stress echocardiography is recommended in
high-risk patients with a previous history of CAD sched-
uled for elective high-risk surgical procedures. The test
is not recommended in low-to-medium-risk patients.
Stress echocardiography in the emergency department
Stress echo has been performed in the ED with several forms
of testing,172,221,334–341 including exercise,338–340 dobuta-
mine,172 and dipyridamole.221 Studies unanimously show a
very high feasibility of stress echo, higher with pharmaco-
logic means than with exercise, with an excellent safety
proﬁle, and with very high negative predictive value of
stress echo results. One study reported the similar prognos-
tic accuracy of stress echo and stress SPECTscintigraphy per-
formed simultaneously in the same patient.339 It is
important to note that the rate of positivity in the screened
population varied considerably, from 3 to 45%. When the
selection criterion is any form of ‘chest pain’, typical or aty-
pical, a very low positivity rate may be expected. If only
patients with high-to-intermediate clinical risk are
screened, the rate of positivity may be substantially
higher.340 Patients with positive stress echo have underlying
coronary artery disease and should be admitted to the CCU.
The efﬁcacy of this algorithm has been shown not only in
single-center experiences but also in large-scale, multicen-
tre validation of the SPEED trial, which analysed more
than 500 patients recruited from six centres from three
different countries.221 The negative predictive value of a
negative algorithm is very high (99%). However, there are
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occasional patients with a negative stress test and early
readmission for acute coronary syndromes. The used algor-
ithms currently in the ED certainly minimize the causes of
error, but cannot unmask every substrate of myocardial
ischaemia. The quest for the ‘optimal’ algorithm in the ED
will certainly continue in the coming years, but rest and
stress echo in the ED are here to stay.
Key point: Stress echocardiography is recommended in
patients with chest pain admitted to the ER for risk stra-
tiﬁcation purposes—especially when ECG stress test is
submaximal, not feasible, or non-diagnostic.
Contraindications
A poor acoustic window makes any form of stress echocar-
diography unfeasible to perform. However, a difﬁcult
resting echocardiography greatly increases the probability
of obtaining no interpretable study results during exercise
and should be an indication for the less technically demand-
ing pharmacological stress echocardiography. However, this
limitation of stress echocardiography today should not
exceed 5% of all referrals. With new transducer technology
using harmonic imaging and the use of intravenous contrast
agents for LV opaciﬁcation (discussed later), optimal endo-
cardial border delineation is achievable in the vast majority
of patients and should be available in every stress echo lab-
oratory. Speciﬁc contraindications to dipyridamole (or ade-
nosine) echocardiography include the presence of severe
conduction disturbances, since adenosine can cause transi-
ent block at the atrio-ventricular node and severe bronchop-
neumopathic disease requiring chronic xantine therapy,
since adenosine is a powerful bronchoconstrictor. Patients
with resting systolic blood pressure under 100 mmHg gener-
ally should not receive dipyridamole and caution should be
taken with dobutamine. In fact, dobutamine causes an
increase in systolic blood pressure in the majority of
patients but can also cause a decrease in systolic blood
pressure in some patients. Dipyridamole usually causes a
modest decrease in systolic blood pressure of 10–
20 mmHg, but occasionally causes more severe decrease.
Adenosine is the preferred option because of its rapid half-
life (,10 s) in patients with unstable carotid artery
disease. Signiﬁcant hypertension and prolonged hypotension
should be avoided in these patients, rendering adenosine
the agent of choice. Patients who do not achieve the
target heart rate with dobutamine alone or inducible ischae-
mia with dipyridamole alone are commonly administered
atropine. Atropine in this setting is a risk only for
closed-angle glaucoma patients, a minority of those with
glaucoma. Severe prostatic disease is also a contraindication
to atropine use.
New technologies applied to stress
echocardiography
The state-of-the art diagnosis of ischaemia in stress echocar-
diography remains the eyeballing interpretation of regional
wall motion in black and white cine-loops. Many new signs
have been proposed but not fully validated in their clinical
meaning: reduced coronary regional perfusion defect by
contrast echo, reduced coronary ﬂow reserve, increased
echodensity and reduced regional cyclic variation by tissue
characterization, altered tissue Doppler imaging and its
derivatives and colour-kinesis, and anatomical M-Mode and
3D echo. These techniques have exciting potential to clini-
cally describe pathophysiological parameters located
upstream in the ischaemic cascade when compared with
regional wall motion abnormalities and to establish the diag-
nosis of myocardial ischaemia in a more quantitative basis.
At present, there is no easy solution to the need to quan-
tify regional function as the problem is complicated by
issues of translational motion, tethering, torsional move-
ment, image quality, and so on.342 With new technologies,
like new drugs, large-scale experience should be gathered
before accepting a catchy description promoted by the
marketing ofﬁces as proven. Like new tests, new technol-
ogies should be viewed critically in the present era of
cost-effectiveness.
Contrast-enhanced echocardiography
The development of contrast media in echocardiography has
been slow. In the past decade, transpulmonary contrast
agents have become commercially available for clinical use.
The approved indication for the use of contrast echocardio-
graphy currently lies in improving endocardial border delinea-
tion in patients in whom adequate imaging is difﬁcult or
suboptimal.343 In coronary artery disease patients, in whom
particular attention should be focused on regionalmyocardial
contraction, clear endocardial deﬁnition is crucial. Intrave-
nous contrast agents can improve endocardial delineation at
rest343 and with stress.344 Training is needed to ensure accu-
rate interpretation of the contrast-enhanced images. When
ultrasound contrast agents are used, contrast-speciﬁc
imaging modalities should be used. The ability of contrast
echocardiography to supplement wall motion information by
providing information on perfusion can add additional diag-
nostic value to stress echocardiography.
Real-time three-dimensional imaging
Technological advances in transducer and computer technol-
ogy have led to the recent introduction of real-time 3D
echocardiography. Similar to 2D echocardiography, contrast
echocardiography can be used for enhancement of endocar-
dial border deﬁnition and possibly for myocardial perfusion.
Initial studies with 3D echocardiography during stress echo-
cardiography have been encouraging;345,346 however, no
data are available on the additional value of this technique
over conventional wall motion interpretation. Matrix probes
used for real-time 3D echocardiography offer the unique
feature of recording all LV segments simultaneously, which
may be advantageous for stress studies.
TDI and derivatives
Tissue Doppler imaging permits the quantitative and repro-
ducible assessment of myocardial velocity and deformation.
Limited signal quality and a learning curve require special
expertise from the user. Although velocity measurements
need regional normal values or complex models for
interpretation, it could be shown that the newly occurring
post-systolic shortening—a known sign of regional ischae-
mia—can be recognizable with deformation imaging and
used for diagnosing ischaemia. No data currently demon-
strate the superiority of quantitative techniques over
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conventional wall motion analysis for the assessment of
viable and ischaemic myocardium.347–351
Key point: No new technology application to stress
echocardiography is routinely recommended except for
contrast for endocardial border enhancement, which
should be used whenever there are suboptimal resting
or peak stress images. Intravenous contrast for LV opaciﬁ-
cation improves endocardial border deﬁnition and may
salvage an otherwise suboptimal study.
Comparison with competing techniques: cost
and risk assessment
Given the many factors affecting the value of diagnostic
accuracy, reliable information on the relative value of
different tests can only be gained by studying an adequate
number of patients in head-to-head comparison under the
same conditions. When compared with standard exercise
electrocardiography testing, stress echocardiography has
an advantage in terms of sensitivity and a particularly
impressive advantage in terms of speciﬁcity.
In recent guidelines, the advantages of stress echocardio-
graphy over perfusion scintigraphy include higher speciﬁcity,
greater versatility, greater convenience, and lower cost.352
The advantages of stress perfusion imaging include a
higher technical success rate, higher sensitivity (especially
for single-vessel disease involving the left circumﬂex),
better accuracy when multiple resting LV wall motion
abnormalities are present, and a more extensive database
for the evaluation of prognosis.352,353 The ESC Guidelines
on stable angina conclude that ‘On the whole, stress echo
and stress perfusion scintigraphy, whether using exercise
or pharmacological stress (inotropic or vasodilator), have
very similar applications. The choice as to which is employed
depends largely on local facilities and expertise’.296 Cardiac
magnetic resonance (CMR) is the latest technique to enter
the ﬁeld of cardiac imaging.354–358 The advantages of the
technique are related to the absence of ionizing radiation,
at the price of higher costs and lower availability when com-
pared with echocardiography. Despite the high costs, the
time of image acquistion, safety proﬁle, and low availability
makes CMR an excellent option only when stress echocardio-
graphy is inconclusive or not feasible.359
The high cost of stress imaging procedures warrants some
ﬁnancial justiﬁcation, and three arguments have been pro-
posed. First, a negative stress imaging test implies such a
low risk of an event that revascularization could not be jus-
tiﬁed on prognostic grounds. Secondly, compared with
simple stress testing, the use of imaging tests in particular
situations has been shown to reduce downstream costs
(both diagnostic and therapeutic). Thirdly, several studies
have shown that in comparison with coronary angiography
(where the detection of coronary stenoses seems to lead
inexorably to coronary intervention), decision-making
based on functional testing is associated with similar out-
comes at lower levels of downstream cost. On the basis of
this large body of evidence assessing the comparable accu-
racy of stress echo and perfusion scintigraphy, the choice
of one test over the other will depend on the overall biologi-
cal risk related to the use of radiations. This is rec-
ommended by the executive European Law (1997) and the
European Commission Medical Imaging Guidelines (2001).
EU Medical Imaging Guidelines and the European law
(Euratom directive 97/43) state that a radiological (and
medico-nuclear) examination can be performed only ‘when
it cannot be replaced by other techniques that do not
employ ionising radiation’ and it should always be justiﬁed
(article 3: ‘if an exposure cannot be justiﬁed it should be
prohibited’). At patient level, the effective dose of a
single nuclear cardiology stress imaging scan ranges from
10 to 27 mSv (with dual isotope imaging protocol). The cor-
responding equivalent dose exposure is 500 chest X-rays
(sestamibi), 1200 chest X-rays (Thallium), and 1300 chest
X-rays (dual isotope protocol). According to the latest and
most authoritative estimates of BEIR VII, the estimated
risk of cancer for a middle-aged patient ranges from 1 in
1000 (for a sestamibi) to 1 in 400 (for a dual isotope scan).
Therefore, in an integrated risk–beneﬁt balance, stress
echo has shown advantages when compared with imaging
techniques such as scintigraphy.360–363
Key point: Stress echocardiography should be preferred
due to it lower cost, wider availability and—most impor-
tantly—for the radiation-free nature. Stress scintigraphy
offers similar information to stress echocardiography,
but with a radiation burden between 600 and 1300
chest X-rays for every single stress scintigraphy. This
poses a signiﬁcant biological risk both for the individual
and for the society, since small individual risks multiplied
by millions stress tests per year become a signiﬁcant
population burden.
The training issue
It is not reasonable to begin using stress echocardiography
without a complete training in transthoracic echocardiogra-
phy, and the EAE accreditation exam is highly recommended.
The basic skills required for imaging the heart under resting
conditions do not differ substantially from those required
for imaging the same heart from the same projections
during stress. The diagnostic accuracy of an experienced
echocardiographer who is an absolute beginner in stress
echocardiography is more or less equivalent to that achieved
by tossing a coin. However, 100 stress echocardiographic
studies are more than adequate to build the individual learn-
ing curve and reach the plateau of diagnostic accuracy.364 It is
wise to do the following: start with low-dose tests for viability
and later progress to tests for ischaemia; start with safer and
easier vasodilator tests and later progress to adrenergic stres-
ses; and start with pharmacological, and then progress to
physical exercise stress echocardiography. In the case of a
patient with a known or suspected infarction, no echocardio-
grapher would make the diagnosis of presence, site, and
extension of dyssynergy on the basis of a single cardiac cycle
in one view from only one approach: the dyssynergy can be
highly localized, and some regions can be adequately visual-
ized only in some projections. An important general rule of
stress echocardiography stems from an obvious fact: all
views that can be obtained should be obtained both in
resting conditions and during stress. It is also evident that
the temporal sampling must be continuous so that the exact
ischaemia-free stress time can be determined and the stress
immediately stopped as soon as an obvious dyssynergy devel-
ops. Today, the interpretation of stress echocardiography is by
necessity qualitative and subjective. Diagnostic accuracy is
not only a function of experience; for a given diagnostic
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accuracy, every observer has his/her own sensitivity–speci-
ﬁcity curve: there are ‘over-readers’ (high sensitivity, low
speciﬁcity) and ‘underreaders’ (low sensitivity, high speci-
ﬁcity), depending on whether images are aggressively or con-
servatively interpreted as abnormal. Many studies are
unquestionably negative or positive; still, there is a ‘grey
zone’ of interpretable tests in which the visualization of
some regions can be suboptimal and the cardiologist’s level
of experience in interpreting the test is critical for a correct
reading. Interobserver variability is certainly a common
problem inmedicine, and in cardiology variability can be sub-
stantial with almost all diagnostic methods, including resting
electrocardiography,365 exercise electrocardiography,366 per-
fusion scintigraphy,367 andcoronary angiography.368 There are
manyprecautions thatmayminimize variability, providingnot
only high accuracy but also better reproducibility. These par-
ameters are related to the physician interpreting the study,
the technology used, the stress employed, and the patient
under study. Variability will be substantially reduced if one
agrees in advance not to consider minor degrees of hypokin-
esis, since mild hypokinesis is a normal variant under most
stresses and a ﬁnding widely overlapping between a normal
and a diseasedpopulation.369–372 The inclusion amongpositiv-
ity criteria of isolated asynergy of basal-infero-lateral or
basal-infero-septal segments will also inﬂate variability.
Obviously, the inclusion of patientswith resting images of bor-
derline quality or the use of stresses degrading image quality
will also dilate variability, which is tightly linked to the quality
of the images. Other factors, including new technologies such
as tissue Doppler have a potential to reduce variability.373
Digital acquisitionmay improve reproducibility.371 In patients
with a difﬁcult acoustic window, native second harmonic
imaging and the use of contrast agents help to improve
accuracy and reduce variability.375,376 Finally, the single
most important factor deﬂating variability is a speciﬁc
course of training in a large-volume stress echocardiography
labwith exposure to joint reading376 and aprioridevelopment
of standardized377 and conservative378 reading criteria.
Key point: It is recommended to perform at least 100
exams under the supervision of an expert reader in a
high-volume laboratory, and ideally with the possibility
of angiographic veriﬁcation, before starting stress echo-
cardiography on a routine basis. Maintenance of compe-
tence requires at least 100 stress echo exams per year.
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